Corindus Vascular Robotics Inc (NYSEMKT:CVRS) received a $3.00 target price from stock analysts at Cowen and Company in a report issued on Wednesday. The firm currently has a “buy” rating on the medical equipment provider’s stock. Cowen and Company’s target price suggests a potential upside of 80.72% from the company’s previous close.
Several other research analysts have also issued reports on the company. Zacks Investment Research lowered Corindus Vascular Robotics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. ValuEngine upgraded Corindus Vascular Robotics from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. BidaskClub lowered Corindus Vascular Robotics from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Finally, B. Riley restated a “buy” rating and issued a $3.00 target price on shares of Corindus Vascular Robotics in a research note on Wednesday, May 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. Corindus Vascular Robotics presently has an average rating of “Hold” and an average price target of $2.67.
Corindus Vascular Robotics (NYSEMKT CVRS) opened at 1.66 on Wednesday. Corindus Vascular Robotics has a one year low of $0.40 and a one year high of $2.25. The stock’s 50 day moving average is $1.79 and its 200 day moving average is $1.25. The firm’s market cap is $310.55 million.
Corindus Vascular Robotics (NYSEMKT:CVRS) last released its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Corindus Vascular Robotics had a negative return on equity of 181.63% and a negative net margin of 1,272.20%. The firm had revenue of $2.26 million during the quarter, compared to analyst estimates of $3.10 million. On average, equities research analysts expect that Corindus Vascular Robotics will post ($0.21) earnings per share for the current year.
WARNING: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://sportsperspectives.com/2017/08/10/cowen-and-company-analysts-give-corindus-vascular-robotics-inc-nysemktcvrs-a-3-00-price-target.html.
A number of institutional investors have recently bought and sold shares of CVRS. Bank of New York Mellon Corp boosted its position in Corindus Vascular Robotics by 40.7% in the second quarter. Bank of New York Mellon Corp now owns 229,380 shares of the medical equipment provider’s stock valued at $426,000 after buying an additional 66,368 shares in the last quarter. Rhumbline Advisers boosted its position in Corindus Vascular Robotics by 67.6% in the second quarter. Rhumbline Advisers now owns 80,868 shares of the medical equipment provider’s stock valued at $150,000 after buying an additional 32,608 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in Corindus Vascular Robotics by 240.4% in the first quarter. Schwab Charles Investment Management Inc. now owns 285,900 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 201,900 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in Corindus Vascular Robotics by 73.3% in the first quarter. Geode Capital Management LLC now owns 673,488 shares of the medical equipment provider’s stock valued at $882,000 after buying an additional 284,855 shares in the last quarter.
Corindus Vascular Robotics Company Profile
Corindus Vascular Robotics, Inc is engaged in robotic-assisted vascular interventions. The Company’s CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries.
Receive News & Ratings for Corindus Vascular Robotics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics Inc and related companies with MarketBeat.com's FREE daily email newsletter.